A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

Completed · Phase 3

Conditions studied: Primary Hyperoxaluria Type 1, Primary Hyperoxaluria

In brief

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in patients with Advanced Primary Hyperoxaluria Type 1 (PH1).

Key facts

Study ID
NCT04152200
Run by
Alnylam Pharmaceuticals
People needed
21
Starts
2020-01-21
Expected to finish
2025-06-23
Last updated by the study team
2025-07-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.